Comparing Two Medicines, Apremilast and Adalimumab, in Psoriatic Arthritis
Compares apremilast and adalimumab, each given with methotrexate, in adults with psoriatic arthritis.
Plain-language title generated from the registry record
Registry title: Apremilast and Adalimumab in Psoriatic Arthritis Patients
Key facts
- Where
- Tanta, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07398651, who can take part
Where in Egypt
- Tanta universityTanta, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT07398651
- Record updated
- 8 September 2026
- Original description
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with MethotrexateRead full original descriptionShow less
Comparative Study Between Apremilast and Adalimumab in Psoriatic Arthritis Patients
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
Inclusion: This study will include 60 adult Psoriatic arthritis patients >18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months; Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains.
Exclusion: Patients who received previous biologic agents or Janus kinase inhibitors; Current or recent serious infection including tuberculosis or hepatitis B/C ; Current or past history of malignancy (within five year); Severe uncontrolled comorbidities such as heart failure, severe liver disease, or chronic kidney disease (eGFR <30 mL/min/1.73m²) ; Patients with axial and ocular involvement; Pregnant or breastfeeding women or women planning pregnancy during the study period .